Welcome to our dedicated page for BIOPLUS ACQUISITION news (Ticker: BIOS), a resource for investors and traders seeking the latest updates and insights on BIOPLUS ACQUISITION stock.
BioPlus Acquisition Corp. (NASDAQ: BIOS) provides investors with comprehensive updates regarding its corporate actions and dissolution process. This dedicated news hub aggregates all material developments related to the SPAC's liquidation, including official communications about shareholder redemptions and regulatory filings.
Key updates include details about the $10.79 per share redemption process for Class A ordinary shares, handling of warrants, and procedural requirements for different shareholder categories. The resource serves as a centralized reference point for understanding timeline-sensitive corporate actions and their implications.
All content undergoes verification against original SEC filings and company announcements to ensure accuracy. Investors can expect updates covering liquidation milestones, transfer agent communications, and regulatory compliance matters. Bookmark this page for streamlined access to BIOS's final corporate developments as the dissolution process unfolds.
The Company, Riverbed|Aternity, announced the appointment of seven new directors to its Board of Directors following its recapitalization, effective December 7, 2021. These seasoned leaders bring diverse skills to enhance strategic goals and customer relationships. CEO Dan Smoot emphasized the Board's alignment with the Company's future vision and its improved financial profile. The new board members include R. Carter Pate, Steve Curts, and Patricia Hume, among others, each with significant experience in various sectors.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 each. The units will begin trading on Nasdaq on December 3, 2021, under the ticker symbol BIOSU. Each unit comprises one Class A share and one-half of a redeemable warrant, which allows the purchase of one Class A share at $11.50. The securities will eventually trade separately under BIOS for shares and BIOSW for warrants. The company focuses on the life sciences sector for its business combinations.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 per unit, set to trade on Nasdaq under the symbol BIOSU starting December 3, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, with each whole warrant allowing the purchase of one share at $11.50. The company aims to pursue mergers or acquisitions primarily within the life sciences sector, with Cantor Fitzgerald & Co. as the sole book-running manager for this offering.
FAQ
What is the market cap of BIOPLUS ACQUISITION (BIOS)?
